Examining Factors That May Influence Resistance to HIV-1 Infection
Prospective Study of the Determinants of Host Resistance to HIV-1 Infection
研究概览
地位
条件
详细说明
Even with repeated exposure to HIV-1, some individuals appear to be resistant to infection. The exact mechanism of this resistance, however, remains unknown. The relative risk of HIV-1 infection appears to depend on various factors: route of transmission, viral load of the infected donor, nature and extent of exposure, presence of sexually transmitted infections (STIs), and genetic and immunological status of the exposed individual. This last factor may explain the inherent ability of some people to remain uninfected despite repeated exposure to HIV-1.
Immune response in HIV-1 exposed uninfected individuals is sometimes characterized by specific cytotoxic CD8 T cell response without antibody response, suggesting that resistance may, in part, be mediated by HIV-1 specific T cells. Exposed uninfected individuals may also be genetically protected, in which case key genes-possibly linked to immune responses-may lead to resistance to HIV-1. A clearer understanding of the role of an individual's genetic and immune-mediated resistance to HIV-1 infection is needed and will provide important information for advancing preventive HIV vaccine design. The purpose of this study is to examine the immune responses of individuals who have been exposed to HIV-1, but who remain uninfected. Through the use of highly sensitive technology, low level immune responses and viral levels will be evaluated. The study will also compare genetic profiles, exposure characteristics, donor viral load, STIs, and sexual behaviors among all participants. In the infected member of a serodiscordant couple, the HIV-1 virus will be examined and sequenced.
This observational study will last approximately 24 months. Screening will involve at least one visit and will occur at least 8 weeks prior to study entry. Eligible participants will fall into one of three groups:
- Group 1 will include individuals who have been exposed to HIV-1 but who remain uninfected.
- Group 2 will include HIV infected regular sexual partners of Group 1 members.
- Group 3 will include HIV uninfected individuals or couples who have not been exposed to HIV-1.
Study visits will occur every 3 months for a total of 8 visits. At all visits, participants will verify address location, complete standardized questionnaires about sexual behaviors, and receive HIV safe sex counseling and free condoms. Blood and urine will be collected to test for HIV, STIs, and pregnancy. All participants will undergo a review of their medical history and a physical examination, including a genital exam for both males and females and a pelvic exam for females. At selected visits, participants may opt to provide additional samples of urine, saliva, genital secretions, breastmilk, and feces for research purposes. Groups 1 and 3 will have HIV testing at all but the first study visit; Group 2 will have no HIV testing, but will be assessed for CD4 cell count at all study visits. Participants requiring clinical care for the management of HIV or STIs will be either treated at the study site or referred for appropriate care.
研究类型
注册 (预期的)
联系人和位置
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria for Groups 1, 2, and 3:
- Willing to provide adequate location information
- Planning to remain in the area for the duration of the study
Inclusion Criteria for Group 1:
- HIV-1 antibody positive AND nucleic acid test (NAT) or p24 antigen negative
- Report unprotected receptive or insertive vaginal, oral, or anal intercourse with Group 2 partner on at least 12 occasions (St. Mary's cohort) or 25 occasions (MRC/UVRI Uganda cohort) during the 12 months prior to screening; the first sexual exposure with Group 2 partner must have occurred at least 10 months prior to screening
Inclusion Criteria for Group 2 (St. Mary's cohort):
- HIV-1 infected at screening, as determined by enzyme immunoassay and western blot
- Documentation of HIV-1 infection for at least 12 months prior to screening, as determined by enzyme immunoassay and western blot
- Willing to provide clinical information about HIV-1 RNA and CD4 cell count
- Report unprotected receptive or insertive vaginal, oral, or anal intercourse with Group 1 partner on at least 12 occasions during the 12 months prior to screening; the first sexual exposure with Group 1 partner must have occurred at least 10 months prior to screening
Inclusion Criteria for Group 2 (MRC/UVRI Uganda cohort):
- HIV-1 infected, as determined by enzyme immunoassay and western blot
- Report unprotected receptive or insertive vaginal, oral, or anal intercourse with Group 1 partner on at least 25 occasions during the 12 months prior to screening; the first sexual exposure with Group 1 partner must have occurred at least 10 months prior to screening
HIV-1 infected for at least 12 months prior to screening, as determined by one of the following criteria:
- Report a past medical history indicating Herpes zoster infection within the prior 5 years or report a medical history indicating WHO Clinical Staging Criteria for HIV/AIDS of III or IV within the prior 5 years, OR
- CD4 cell count no greater than 450/mm3 for females or no greater than 400/mm3 for males
Report no prior HIV testing, test HIV-1 seropositive at screening, and meet one of the following criteria:
- Report a past medical history indicating Herpes zoster infection within the prior 5 years or report a past medical history indicating WHO Clinical Staging Criteria for HIV/AIDS of III or IV in the prior 5 years, OR
- CD4 cell count no greater than 450/mm3 for females or no greater than 400/mm3 for males
Inclusion Criteria for Group 3:
- HIV-1 antibody negative AND nucleic acid test (NAT) or p24 antigen negative
- Test negative for Neisseria gonorrhoeae, syphilis, Chlamydia trachomatis, and trichomoniasis (MRC/UVRI Uganda cohort only)
- Report a monogamous relationship of at least 12 months duration prior to screening
Exclusion Criteria for Groups 1, 2, and 3:
- Injection drug use in the 5 years prior to screening
- Any condition that, in the opinion of the investigator, would be unsafe or interfere with the study
- Any obligations that may require long absences from the area
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
1
Inidividuals who have been exposed to HIV but remain uninfected.
|
2
HIV infected regular sexual partners of Group 1 participants.
|
3
HIV uninfected individuals or couples who have not been exposed to HIV.
|
合作者和调查者
调查人员
- 学习椅:Andrew J. McMichael, MD, PhD、University of Oxford, Weatherall Institute of Molecular Medicine
出版物和有用的链接
一般刊物
- O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet. 2004 Jun;36(6):565-74. doi: 10.1038/ng1369.
- An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O'Brien SJ, Telenti A, Winkler CA. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol. 2004 Oct;78(20):11070-6. doi: 10.1128/JVI.78.20.11070-11076.2004.
- Kebba A, Kaleebu P, Rowland S, Ingram R, Whitworth J, Imami N, Gotch F. Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis. 2004 May 1;189(9):1705-13. doi: 10.1086/383227. Epub 2004 Apr 19.
- Kebba A, Kaleebu P, Serwanga J, Rowland S, Yirrell D, Downing R, Gilmour J, Imami N, Gotch F, Whitworth J. HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans. AIDS Res Hum Retroviruses. 2004 Jan;20(1):67-75. doi: 10.1089/088922204322749512.
- Missale G, Papagno L, Penna A, Pilli M, Zerbini A, Vitali P, Pieroni G, Urbani S, Uggeri J, Pinheiro S, Rowland-Jones S, Ferrari C. Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection. Eur J Immunol. 2004 Nov;34(11):3208-15. doi: 10.1002/eji.200424889.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
艾滋病毒感染的临床试验
-
Hospital Clinic of Barcelona完全的
-
Centers for Disease Control and PreventionGilead Sciences; CDC Foundation完全的
-
Rajavithi Hospital未知研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的免疫状态 | 研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的 HIV 病毒载量泰国
-
National Institute of Allergy and Infectious Diseases...完全的HIV-1 感染 | HIV抗体 | 中和抗体 | 病毒载量 | 单克隆抗体美国
-
AIDS Healthcare FoundationUniversity of California, Los Angeles完全的
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University of Bergen; Centre... 和其他合作者完全的
-
Hospital Universitari Vall d'Hebron Research InstituteGilead Sciences完全的
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixa完全的